Cosmos Health Inc. 8K

Cosmos Health Inc. reported record Q2 and H1 2026 revenues, improved adjusted profitability metrics, balance sheet deleveraging, and active share repurchases, alongside strategic expansion and financing initiatives, via a press release furnished on Form 8-K.

Cosmos Health Inc. filed a Form 8-K to furnish a press release announcing record financial results for the second quarter and first half of 2026, highlighted by Q2 revenue of $19.0 million and H1 revenue of $36.9 million (up roughly 29–30% year over year), significant improvement in adjusted gross profit and margins, a strengthened balance sheet with total liabilities reduced by 13% and stockholders’ equity up 12%, and the active execution of a previously authorized $5 million share repurchase program under which the company has already repurchased over 5.1 million shares. The release also details strong operating performance across business segments, expansion of proprietary brands and contract manufacturing, progress in U.S. and international markets, the inauguration of new production capabilities, an advisory agreement with the European Investment Bank for potential €25 million R&D financing, identification of around $20 million in non-core assets for potential monetization, a letter of intent to acquire Doc Pharma S.A., and the expiration of a large block of Series B warrants without exercise, all framed as steps toward achieving scale, operating leverage, and eventual profitability despite current GAAP net losses driven partly by non-cash charges.

Filing Facts

CIK

1474167

Ticker

-

Form

8K

Source Type

sec

Accession

0001477932-26-005195

Alert Tier

7